Affimed
is a Germany-based biotechnology company that develops and commercializes antibody therapeutics for the treatment of cancer... Read moreAffimed
is a Germany-based biotechnology company that develops and commercializes antibody therapeutics for the treatment of cancer... Read more
News
May 14, 2025
Seeking Alpha
Affimed: Immuno-oncology company Affimed to be delisted from Nasdaq after insolvency filing
Apr 29, 2025
centralcharts
Press Release: Affimed : Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
Apr 23, 2025
Benzinga
Affimed: Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
Apr 22, 2025
Seeking Alpha
Affimed: Affimed receives Nasdaq non-compliance notice
Mar 25, 2025
Benzinga
Affimed: Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
Mar 03, 2025
Yahoo
Affimed: Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
Dec 17, 2024
RTTNews
Affimed: Affimed Reports Positive Data From AFM24-102 Trial In Heavily Pretreated NSCLC Patients
Dec 09, 2024
Seeking Alpha
Affimed: Affimed reports data from mid-stage study of its lymphoma treatment
Dec 09, 2024
centralcharts
Press Release: Affimed : Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Dec 09, 2024
Benzinga
Affimed: Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
Affimed Competitors
1
2
3
4
5
6
7
8
9
10